tiprankstipranks

Adaptive Biotechnologies price target lowered to $11 from $12 at JPMorgan

JPMorgan lowered the firm’s price target on Adaptive Biotechnologies to $11 from $12 and keeps an Overweight rating on the shares post the Q3 report. The analyst acknowledges the “noisy quarter” but remains encouraged by the continued progress on ClonoSeq.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on ADPT:

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue